11th World Affordable Medicine Congress

11th World Affordable Medicine Congress 7 - 8 February 2017, Barcelona, Spain.
The Annual World Affordable Medicine Congress comes to Barcelona, this is the newly rebranded World Generic Medicines Congress and Biosimilar Drug Development World. For 11 years, the biggest and best in the industry. Through a series of interactives presentation, speed networking and stream sessions, the congress will provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Don't miss out the opportunity to share your experience and network with senior and board level executives working in generic and biosimilar organisations.

Don't miss your chance to hear from:

  • Klaus Martin, Chief Scientific Officer, Polpharma Biologics
  • Matthew Turner, Global Medical Director Biosimilars, Merck
  • Bernd Liedert, Sr.Clinical Program Leader Biosimilars, Boehringer Ingelheim
  • Isabel Afonso, Head of Global Commercial Strategy and member of the Sandoz Executive Committee, Sandoz
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency
  • Adrian Thomas, Vice President of Health Economics & Market Access, Janssen North America

Download the brochure now to see who's speaking.

World Pharma News readers can benefit from an exclusive 10% discount. Quote discount code CGNN

For further information, please visit:
http://www.healthnetworkcommunications.com/conference/affordable-medicines/

About World Affordable Medicine Congress
The World Affordable Medicine Congress Europe brings together two world class events - World Generic Medicines Congress and Biosimilar Drug Development World - that have been central to the industry’s business and networking needs for over 10 years. Over 2000 business leaders participants have benefited from this series since 2007.

The event unites senior executives from the generic and biosimilar industry to provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Amgen and Humana partner for improved health outco…

Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to i...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]